JP2014503206A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503206A5
JP2014503206A5 JP2013544747A JP2013544747A JP2014503206A5 JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5 JP 2013544747 A JP2013544747 A JP 2013544747A JP 2013544747 A JP2013544747 A JP 2013544747A JP 2014503206 A5 JP2014503206 A5 JP 2014503206A5
Authority
JP
Japan
Prior art keywords
recombinant
adenoviral
adenoviral vector
vector
antigen protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013544747A
Other languages
English (en)
Japanese (ja)
Other versions
JP6054876B2 (ja
JP2014503206A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/064944 external-priority patent/WO2012082918A1/en
Publication of JP2014503206A publication Critical patent/JP2014503206A/ja
Publication of JP2014503206A5 publication Critical patent/JP2014503206A5/ja
Application granted granted Critical
Publication of JP6054876B2 publication Critical patent/JP6054876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013544747A 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン Active JP6054876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295410P 2010-12-14 2010-12-14
US61/422,954 2010-12-14
PCT/US2011/064944 WO2012082918A1 (en) 2010-12-14 2011-12-14 Adenovirus serotype 26 and serotype 35 filovirus vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016206679A Division JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Publications (3)

Publication Number Publication Date
JP2014503206A JP2014503206A (ja) 2014-02-13
JP2014503206A5 true JP2014503206A5 (https=) 2015-01-29
JP6054876B2 JP6054876B2 (ja) 2016-12-27

Family

ID=46245095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013544747A Active JP6054876B2 (ja) 2010-12-14 2011-12-14 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016206679A Active JP6268258B2 (ja) 2010-12-14 2016-10-21 アデノウイルス血清型２６および血清型３５のフィロウイルスワクチン

Country Status (14)

Country Link
US (1) US9701718B2 (https=)
EP (1) EP2655604B1 (https=)
JP (2) JP6054876B2 (https=)
KR (1) KR101879892B1 (https=)
CN (1) CN103370411B (https=)
AU (1) AU2011343798B2 (https=)
BR (1) BR112013014712B1 (https=)
CA (1) CA2821289C (https=)
DK (1) DK2655604T3 (https=)
EA (1) EA029504B1 (https=)
ES (1) ES2676196T3 (https=)
PL (1) PL2655604T3 (https=)
WO (1) WO2012082918A1 (https=)
ZA (1) ZA201304260B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2655604T3 (en) 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
WO2015197820A1 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2017002890A (es) 2014-09-03 2017-11-13 Bavarian Nordic As Métodos y composiciones para potenciar respuestas inmunitarias.
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
ES2836432T3 (es) 2015-03-18 2021-06-25 Janssen Vaccines & Prevention Bv Ensayos para sistemas de expresión recombinante
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
WO2017143174A1 (en) 2016-02-18 2017-08-24 International Flavors & Fragrances Inc. Polyurea capsule compositions
ES2876160T3 (es) 2016-03-18 2021-11-12 Int Flavors & Fragrances Inc Microcápsulas de sílice y métodos para prepararlas
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
US11540985B2 (en) 2016-07-01 2023-01-03 International Flavors & Fragrances Inc. Stable microcapsule compositions
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018011198A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
ES2950434T3 (es) 2016-09-16 2023-10-10 Int Flavors & Fragrances Inc Composiciones de microcápsula estabilizadas con agentes de control de la viscosidad
US20180085291A1 (en) 2016-09-28 2018-03-29 International Flavors & Fragrances Inc. Microcapsule compositions containing amino silicone
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
US20180346648A1 (en) 2017-05-30 2018-12-06 International Flavors & Fragrances Inc. Branched polyethyleneimine microcapsules
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
JP7311489B2 (ja) * 2017-07-28 2023-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
BR112020007884A2 (pt) 2017-11-20 2020-11-03 Janssen Pharmaceuticals, Inc. método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
CN111741766A (zh) 2017-12-19 2020-10-02 杨森科学爱尔兰无限公司 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
BR112020021814B1 (pt) 2018-04-27 2023-10-10 International Flavors & Fragrances Inc Composição de microcápsula, métodos para preparar uma composição de microcápsula e para conferir uma sensação de limpeza e frescor a um produto de tecido ou um produto de cuidados com os cabelos, e, produto de consumo
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
WO2020064621A1 (en) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components
EP3897524A4 (en) 2018-12-18 2023-04-26 International Flavors & Fragrances Inc. PROTEIN MICROCAPSULES AND PROCESS FOR THE PRODUCTION THEREOF
EP3897521A4 (en) 2018-12-18 2023-01-25 International Flavors & Fragrances Inc. GUARGUM MICROCAPSULES
AU2020274632A1 (en) 2019-05-14 2021-12-09 Janssen Biotech, Inc. Efficient impurity removal using a diafiltration process
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
MX2022014162A (es) 2020-05-11 2023-02-23 Janssen Pharmaceuticals Inc Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
MX2023000024A (es) 2020-06-29 2023-04-12 Janssen Vaccines & Prevention Bv Combinación vacunal contra la infección por el virus respiratorio sincicial.
JP2023532369A (ja) 2020-07-06 2023-07-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
EA037291B9 (ru) * 2020-08-22 2021-11-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты)
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
EP4124383A1 (en) 2021-07-27 2023-02-01 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4154974A1 (en) 2021-09-23 2023-03-29 International Flavors & Fragrances Inc. Biodegradable microcapsules
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
CN120344553A (zh) 2022-10-06 2025-07-18 Msd国际商务股份有限公司 稳定的融合前piv3 f蛋白
EP4406641A1 (en) 2023-01-26 2024-07-31 International Flavors & Fragrances Inc. Biodegradable microcapsules containing low log p fragrance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852324B1 (en) * 1997-12-23 2005-02-08 The United States Of America As Represented By The Department Of Health And Human Services Immunization for ebola virus infection
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003028632A2 (en) 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2005012538A2 (en) * 2003-08-01 2005-02-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Accelerated vaccination
AU2005289439B2 (en) * 2004-09-27 2011-12-01 Crucell Holland B.V. Optimized vaccines to provide protection against Ebola and other viruses
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
JP4843613B2 (ja) * 2004-10-13 2011-12-21 クルセル ホランド ベー ヴェー 改良されたアデノウイルスベクターおよびその使用方法
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
DK2655604T3 (en) 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES

Similar Documents

Publication Publication Date Title
JP2014503206A5 (https=)
Martin et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Fausther-Bovendo et al. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
JP2020528911A5 (https=)
JP2019530462A5 (https=)
JP2014502156A5 (https=)
JP2016506416A5 (https=)
JP2018520997A5 (https=)
JP2016510989A5 (https=)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
JP2015533841A5 (https=)
JP2011530309A5 (https=)
JP2005523318A5 (https=)
JP2016539946A5 (https=)
JP2012126742A5 (https=)
JP2016538885A5 (https=)
JP2014516536A5 (https=)
JP2013507907A5 (https=)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
JP2016534034A5 (https=)
RU2017113571A (ru) Рекомбинантные вакцины от fmdv и их применение
JP2016513115A5 (https=)
JP2015524422A5 (https=)
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
JP2019526580A5 (https=)